Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
Friday, December 10, 2010 - 10:20
in Health & Medicine
Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer.